{"filing":{"accession_number":"0001193125-26-389836","cik":"0001661998","ticker":"QTTB","company_name":"Q32 Bio Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"d158730d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526389836/d158730d8k.htm"},"events":[{"id":33107,"run_id":30431,"accession_number":"0001193125-26-389836","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Q32 Bio appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Both appointments are material to the clinical-stage biotech company as these key leadership roles directly oversee clinical development and regulatory strategy for the company's late-stage clinical program (bempikibart in Phase 2 for alopecia areata).","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36455,"accession_number":"0001193125-26-389836","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two senior executives: José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Both appointments are material to a clinical-stage biotech company advancing a late-stage clinical program (bempikibart in Phase 2 for alopecia areata), as these are key leadership roles directly overseeing clinical development and regulatory strategy. The press release emphasizes their extensive experience and the \"pivotal moment\" of the company's transition into late-stage development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:16:51.290311+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36456,"accession_number":"0001193125-26-389836","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two senior executives: José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Both appointments are material to a clinical-stage biotech company advancing a lead candidate (bempikibart) into late-stage development, as these roles are critical to regulatory strategy and clinical execution. The press release emphasizes their extensive experience in late-stage development and regulatory approval, directly supporting the company's transition into registration-directed programs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:16:51.290311+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36455,"accession_number":"0001193125-26-389836","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two senior executives: José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Both appointments are material to a clinical-stage biotech company advancing a late-stage clinical program (bempikibart in Phase 2 for alopecia areata), as these are key leadership roles directly overseeing clinical development and regulatory strategy. The press release emphasizes their extensive experience and the \"pivotal moment\" of the company's transition into late-stage development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:16:51.290311+00:00","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-09-14"},{"id":36456,"accession_number":"0001193125-26-389836","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two senior executives: José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Both appointments are material to a clinical-stage biotech company advancing a lead candidate (bempikibart) into late-stage development, as these roles are critical to regulatory strategy and clinical execution. The press release emphasizes their extensive experience in late-stage development and regulatory approval, directly supporting the company's transition into registration-directed programs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:16:51.290311+00:00","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-09-14"}]}